Genetic dementia

Genetic dementia (also referred to as hereditary dementia or familial dementia) is a broad grouping of inherited neurodegenerative disorders characterized by progressive cognitive decline, behavioral changes, and loss of the ability to perform daily activities. These conditions primarily affect the central nervous system, with progressive deterioration of brain structures leading to impairments in memory, language, executive function, visuospatial abilities, and personality. The category encompasses several well-recognized entities including familial Alzheimer disease (caused by mutations in genes such as APP, PSEN1, and PSEN2), familial frontotemporal dementia (associated with mutations in MAPT, GRN, and C9orf72), familial prion diseases (PRNK gene mutations causing conditions like Gerstmann-Sträussler-Scheinker syndrome and fatal familial insomnia), CADASIL (NOTCH3 mutations causing vascular dementia), and Huntington disease (HTT gene), among others. The age of onset varies considerably depending on the specific genetic subtype. Familial Alzheimer disease due to PSEN1 mutations can present as early as the third decade of life, while other forms may not manifest until later adulthood. Symptoms typically begin insidiously with memory difficulties or personality changes and progress over years to severe cognitive impairment, motor dysfunction, and eventually complete dependence on caregivers. Psychiatric symptoms including depression, anxiety, agitation, and psychosis are common across many subtypes. Some forms also involve movement abnormalities such as parkinsonism, myoclonus, or chorea. Currently, there are no curative treatments for genetic dementias. Management is primarily supportive and symptomatic, including cholinesterase inhibitors and memantine for cognitive symptoms in Alzheimer-type presentations, behavioral interventions, and comprehensive multidisciplinary care. Genetic counseling is essential for affected families to understand inheritance risks and reproductive options. Research into disease-modifying therapies, including gene-targeted approaches and anti-amyloid antibodies for familial Alzheimer disease, is actively ongoing and represents a promising area of development.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic dementia